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ORIGINAL RESEARCH
Background: A variety of factors contribute to the development of cognitive impairment in
elderly people. Previous studies have focused upon a single or a few risk factors. In this study
we assessed and compared the significance of a wide variety of potential risk factors for
cognitive impairment in postmenopausal women.
Methods: A total of 208 pairs of elderly women (mean age = 73.2 years) were examined in a
cross-sectional case-control study. Each pair consisted of a case (with impaired cognition)
and a control subject matched by age and educational status. Cognitive functions were
determined using a modified version of the Blessed test. Participants were also subjected to a
general clinical examination and they were interviewed to collect information on lifestyle
practices and comorbid disorders. Genotypes for the apolipoprotein E (APOE) epsilon4,
catechol-O-methyltransferase (COMT) Val/Met, and brain-derived neurotropic growth factor
(BDNF) Val/Met polymorphisms were determined. Data were analyzed by conditional logistic
regression.
Results: We identified a set of risk factors for age-related cognitive impairment. A statistical
model for assessment of the importance of these factors was constructed. The factors in
this model were physical exercise (odds ratio [OR] = 0.50, 95% confidence interval
[CI] = 0.32–0.78), regular alcohol consumption (OR = 0.49, 95% CI = 0.29–0.83), metabolic
syndrome (OR = 2.83, 95% CI = 1.26–6.39), depression (OR = 3.24, 95% CI = 1.28–8.22), and
the APOE epsilon4 allele (OR = 1.76, 95% CI = 1.09–2.83). Also COMT genotype was present
as a risk factor in the statistical model (p = 0.08).
Conclusions: Lifestyle risk factors, comorbid disorders, and genetic factors contribute to
development of age-related cognitive impairment. The two former groups of risk factors appear
to be particular important in this respect.
Keywords: age-related cognitive impairment, risk factors, lifestyle choices, comorbid
disorders, genetic susceptibility
Introduction
Aging is accompanied by a decline in cognitive abilities, which may lead to dementia.
The prevalence of dementia is expected to rise in the upcoming decade due to an
increasing longevity in several regions of the world. Major consequences of cognitive
decline in elderly people include impaired quality of life, loss of social functions,
and ultimately total dependence of home care services or hospitalization, demanding
enormous financial resources from public health systems (Fillit et al 2002).
Consequently, great efforts have been invested in order to identify risk factors
implicated in age-dependent cognitive decline and to preserve cognitive vitality in
the elderly.
Several genetic and environmental factors affect the risk for age-related cognitive
impairment. Factors with a protective effect on cognitive abilities include physical
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exercise (Laurin et al 2001), vitamin supplementation
(Grodstein et al 2003), and moderate consumption of
alcohol, while excessive alcohol consumption has adverse
effects (for a review of the effects of alcohol, see Pinder
and Sandler 2004). Another factor of potential importance
to cognitive abilities is tobacco smoking, which has been
reported to increase the risk for cognitive impairment and
dementia (Ott et al 2004; Atkinson et al 2005; Whalley et al
2005). Contradictory findings suggesting a protective effect
of nicotine on the aging of the brain have also been made
by some epidemiological studies (for a review, see Sabbagh
et al 2002). However, these studies may have suffered from
unrecognized biases (Kukull 2001). Of particular relevance
to postmenopausal women is that estrogen deficiency may
promote development of central obesity and metabolic
syndrome. This syndrome, characterized by hypertension,
obesity, dyslipidemia, and glucose intolerance (Wilkin and
Voss 2004), has previously been implicated in the
development of age-related cognitive impairment and
dementia (Stewart and Liolitsa 1999; Yaffe et al 2004). In
addition, depression appears to be involved in cognitive
impairment in the elderly, possibly by alteration of
fundamental processes in the brain (Yaffe et al 1999; Wilson
et al 2004).
Candidate genes assessed for their potential contribution
to dementia include the apolipoprotein E gene (APOE). A
polymorphic variant of this gene termed the APOE epsilon4
allele has been associated with an accelerated loss of
cognitive abilities in elderly people, especially women
(Hyman et al 1996). This allele also seems capable of
modulating the effects of alcohol on cognition in elderly
people (Dufouil et al 2000; Mukamal et al 2003). Since aging
is accompanied by a decline in the function of the
dopaminergic system (Kaasinen et al 2002), a transmitter
system of crucial importance to cognitive processes, genetic
polymorphisms modulating the levels of this transmitter
might also be involved in age-related cognitive decline.
Catechol-O-methyltranferase is an enzyme implicated in the
catabolism of dopamine and other catecholamines. The Met
allele of the catechol-O-methyltransferase (COMT) Val/Met
polymorphism has been associated with decreased
enzymatic activity (Lachman et al 1996) and improved
prefrontal cortex functioning (Egan et al 2001). Another
plausible modulator of cognitive function is brain-derived
neurotropic growth factor (BDNF), which enhances
neuronal transmission and has neuroprotective properties
(Russo-Neustad 2003). The Val/Met polymorphism of the
BDNF gene influences memory functions (Egan et al 2003;
Hariri et al 2003).
The majority of earlier studies have focused on the role
of a single or a few risk factors in age-related cognitive
impairment. The aim of the present study was to identify a
set of risk factors for cognitive dysfunction in elderly
postmenopausal women and assess their relative importance
allowing effective preventive measures to be taken.
Methods
The investigation was undertaken as a matched case-control
study of 208 pairs of elderly women. These women were
selected from the PERF (Prospective Epidemiological Risk
Factors) study cohort, which includes 5847 postmenopausal
women (Bagger et al 2004). Information on demographic
characteristics, lifestyle practices, and medical history,
including occurrence of depression, possible use of hormone
replacement therapy (HRT), and occurrence of various
diseases among relatives was gathered by a personal
interview applying a questionnaire. About half of the women
with a history of depression reported that they were in
ongoing treatment with an antidepressant at the time of the
interview.
Within the PERF cohort a total of 220 women (mean
age: 73.2 ± 6.4 years) were cognitively impaired as
determined by a modified version of the Blessed test, the
6-item Orientation-Memory-Concentration test (Katzman
et al 1983). The results achieved by this test are highly
correlated with those obtained by more extensive tests for
assessment of mental-status functioning in elderly (Stuss et
al 1996). Due to a lack of DNA samples from some of the
women, only 208 observation pairs were included in the
study. Each of these pairs consisted of a case (cognitive score
≥ 9) and a control subject (cognitive score = 0) matched by
age and educational level (an indicator of socioeconomic
status).
Lifestyle factors in the questionnaire included frequency
of physical exercise (0, 1, 2, or > 2 times per week), smoking
habits (< 10, 10–20, or > 20 cigarettes per day), use of
vitamin pills during the winter, and alcohol consumption
(< 7, 7–14, or > 14 units per week, where 1 unit denotes a
bottle of beer with a content of 330 mL or a standard-size
glass of wine of 120 mL). The majority of the women who
reported regular use of alcohol (> 80%) stated that they
preferentially consumed red wine. Eighteen women reported
an alcohol intake of more than 14 units per week but none
of these women were abusersNeuropsychiatric Disease and Treatment 2006:2(2) 229
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At the time of interview, the women were subjected to a
general medical examination. This included determination
of body mass index (BMI), which was calculated as body
weight in kg divided by squared height in m. We used BMI
≥ 27.5 kg/m
2 as cutoff for definition of obesity. Systolic and
diastolic arterial blood pressures were measured applying a
digital blood pressure monitor (UA-777, A&D Instruments
Ltd, Oxford, UK). Hypertension was defined as elevated
systolic blood pressure (≥ 160 mmHg), elevated diastolic
blood pressure (≥ 90 mmHg), or use of antihypertensive
agents. Serum triglyceride level was determined in samples
collected after at least 10 hours of fasting using an automatic
blood analyzer (Vitros
® 250 Chemistry System, Johnson &
Johnson Clinical Diagnostics, Rochester, NY, USA).
Triglyceride levels ≥ 1.69 mmol/L were considered elevated
(hypertriglyceridemia). Metabolic syndrome was defined
as hypertriglyceridemia combined with obesity.
DNA was isolated from peripheral blood samples. APOE
epsilon2, epsilon3, and epsilon4 alleles were determined
by enzymatic amplification and restriction enzyme treatment
of amplified products (Ossendorf and Prellwitz 2000).
Briefly, amplified products were treated with AflII and HaeII,
respectively, followed by electrophoretic separation in
agarose gels. The sequences of the amplification primers
were 5´-ACTGACCCCGGTGGCGGAGGAGACGCGT
GC-3´ and 5´-TGTTCCACCAGGGGCCCCAGGCGCT
CGCGG-3´. The former was deliberately designed with a
mismatch (underlined) to create a nonpolymorphic AflIII
site permitting assessment of the efficiency of the digestion
process.
Genotyping of the COMT Val/Met polymorphism and
the BDNF Val/Met polymorphism was carried out using the
5´ exonuclease technique (Livak et al 1999). The sequences
of the amplification primers for genotyping of the COMT
gene polymorphism were 5´-CCCAGCGGATGGTGGAT-
3´ and 5´-AACGGGTCAGGCATGCA-3´. The probe
sequences were 5´-TGTCCTTCATGCCAGC-3´ and 5´-
CCTTCACGCCAGCGA-3´. The probes were 5´-labeled
with VIC and 6-FAM reporter dyes, respectively, and
conjugated with a minor groove binder group and a
nonfluorescent quencher in their 3´ ends. Genotyping of the
BDNF Val/Met polymorphism was accomplished using
Assay-on-Demand™ reagents (Applied Biosystems, Foster
City, CA, USA). The ABI Prism
® 7000 Sequence Detection
System from the same company served as technical platform
for the 5´ exonuclease-based genotyping assays.
All women had given their written informed consent to
participate. The study was carried out in compliance with
the Helsinki Declaration II and the European Standards for
Good Clinical Practice. The Danish Scientific Ethical
Committee and the Danish Data Protection Agency had
approved the study protocol.
Data were analyzed by conditional logistic regression
with cognitive status as the dependent variable. Initially,
univariate analyses of possible risk factors were carried out.
Factors emerging as important by these analyses were
entered into a multivariate model and subjected to backward
elimination with premove = 0.10. Test for interaction between
the APOE epsilon4 allele and alcohol consumption was
carried out by comparison of models with and without this
interaction term. Assessment of the regression fit was done
by calculation and inspection of standardized delta-beta
values (Pregibon 1984). Odds ratios (ORs) for each of the
risk factors and their 95% confidence intervals (CI) were
determined. Throughout the study, p values < 0.05 were
considered statistically significant. All statistical analyses
were performed using the Egret
® statistical program (Cytel
Software Corporation, Cambridge, MA, USA).
Results
Initially, associations of individual risk factors with cognitive
impairment were assessed (Table 1). For exercise a dose-
dependent and inverse relationship was found (p = 0.01).
Amalgamation of the three higher levels of physical exercise
(1, 2, and > 2 times per week), while maintaining no exercise
as a separate category produced a stronger association with
cognitive performance (p = 0.002), reflecting a low OR for
the exercise group (OR = 0.54, 95% CI = 0.37–0.81).
Consumption of alcohol was associated with a decreased
risk for cognitive impairment (p = 0.01). This decrease was
most pronounced with a medium–moderate consumption
of 7–14 units per week. The relation between amounts of
alcohol consumed and risk for cognitive impairment
produced a U-shaped curve. To increase the statistical power
we collapsed the two categories of regular alcohol
consumption (7–14 units per week and > 14 units per week)
and maintained infrequent alcohol consumption (< 7 units
per week) as a separate category. Analysis of this binary
variable revealed a strong and inverse association between
alcohol consumption and cognitive status (OR = 0.51, 95%
CI = 0.32–0.81, p = 0.003).
Smoking status was not significantly associated with
cognitive performance (p = 0.53). Post-hoc analysis of light
smokers and nonsmokers vs heavy smokers revealed an
increased OR for the latter group but significance was not
reached (OR = 1.75, 95% CI = 0.51–5.98, p = 0.36). We foundNeuropsychiatric Disease and Treatment 2006:2(2) 230
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an association of borderline significance between use of
vitamins in the winter and cognitive impairment (OR = 0.67,
95% CI = 0.44–1.02, p = 0.06).
Obesity (BMI ≥ 27.5 kg/m2) was found to be associated
with cognitive impairment (OR = 1.54, 95% CI = 1.00–2.36,
p = 0.04). A marginal association was found for hyper-
triglyceridemia, ie, triglyceride level ≥ 1.69 mmol/L
(OR = 1.44, 95% CI = 0.92–2.26, p = 0.11). Coexistence of
these two measures of metabolic disturbances conferred a
significantly elevated risk for cognitive impairment
(OR = 2.40, 95% CI = 1.15–5.02, p = 0.01). Hypertension, ie,
systolic blood pressure ≥ 160 mmHg, diastolic blood
pressure ≥ 90 mmHg or use of an antihypertensive agent,
was associated with an increased risk for cognitive
impairment but without approaching statistical significance
(OR = 1.23, 95% CI = 0.84–1.81, p = 0.28). Only 9 women
had received HRT. No statistically significant association
was found between HRT and cognitive performance (data
not shown).
Depression was significantly associated with cognitive
impairment (OR = 3.00, 95% CI = 1.28–7.06, p = 0.01).
Occurrence of dementia among first-degree relatives
increased the OR for cognitive impairment but failed to reach
statistical significance (OR = 1.56, 95% CI = 0.67–3.59,
p = 0.30).
We found a significant association between APOE
epsilon4-carrier status (presence of the epsilon4 allele either
in a homozygous or in a heterozygous state) and cognitive
impairment (OR = 1.61, 95% CI = 1.06–2.44, p = 0.02). The
COMT Val/Met polymorphism was marginally associated
with cognitive impairment (p = 0.10). This reflected a
decreased risk of the COMT Val/Met heterozygous genotype
relative to the two homozygous genotypes. Statistical
significance was not reached for an association of BNDF
genotype with cognitive impairment (p = 0.25).
On backward elimination we derived a model, which
included exercise (treated as a binary variable), consumption
of alcohol (treated as a binary variable), metabolic
syndrome, depression, APOE epsilon4 carrier status, and
COMT Val/Met genotype status (Table 2). Physical exercise,
regular alcohol consumption, metabolic syndrome, and
depression were the variables most strongly associated with
cognitive impairment in this model. The magnitude of the
coefficients in the multivariate model did not deviate by
more than 20% from those determined by the univariate
analyses. The association between COMT genotype status
and cognitive impairment became slightly more pronounced
after correction for the other variables in the model (p = 0.08).
Table 1 Univariate conditional logistic regression analysis of
possible risk factors for cognitive impairment in elderly women
Variable OR (95% CI) p valuea
Frequency of exercise per week 0.01
None Referent
1 0.65 (0.38–1.13)
2 0.60 (0.31–1.17)
> 2 0.47 (0.29–0.75)
None (referent) vs ≥ 1 0.54 (0.37–0.81) 0.002
Alcohol – number of glasses per week 0.01
< 7 Referent
7–14 0.47 (0.28–0.81)
> 14 0.64 (0.26–1.57)
< 7 (referent) vs ≥ 7 0.51 (0.32–0.81) 0.003
Smoking status – number of
cigarettes per day 0.53
< 10 Referent
10–20 0.85 (0.52–1.38)
> 20 1.70 (0.50–5.82)
≤ 20 (referent) vs > 20 1.75 (0.51–5.98) 0.36
Vitamin supplementation during
the winter 0.06
No Referent
Yes 0.67 (0.44–1.02)
BMI 0.04
< 27.5 Referent
≥27.5 1.54 (1.00–2.36)
Hypertriglyceridemia
b 0.11
No Referent
Yes 1.44 (0.92–2.26)
Metabolic syndrome
c 0.01
No Referent
Yes 2.40 (1.15–5.02)
Depression 0.01
No Referent
Yes 3.00 (1.28–7.06)
APOE epsilon4-carrier 0.02
No Referent
Yes 1.61 (1.06–2.44)
COMT Val/Met polymorphism 0.10
Val/Val Referent
Val/Met 0.80 (0.50–1.28)
Met/Met 1.28 (0.74–2.23)
BDNF Val/Met polymorphism 0.25
Val/Val Referent
Val/Met 1.40 (0.91–2.15)
Met/Met 1.48 (0.64–3.46)
a The p values are for likelihood ratio statistics.
b Hypertriglyceridemia was defined as levels ≥ 1.69 mmol/L.
c Metabolic syndrome was defined as hypertriglyceridemia combined with
obesity (BMI ≥ 27.5 kg/m
2).
Abbreviations: APOE, apolipoprotein E; BDNF, brain-derived neurotropic
growth factor; BMI, body mass index; CI, confidence interval; COMT, catechol-O-
methyltransferase; OR, odds ratio.Neuropsychiatric Disease and Treatment 2006:2(2) 231
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We were unable to detect interaction between APOE
epsilon4 genotype status and alcohol consumption (p = 0.84).
Overall, the number of discordant pairs (observation pairs
in which either the case or the control subject is exposed)
was high and approached 100 for the variables included in
the model. Exceptions to this were depression and metabolic
syndrome with 28 and 34 discordant pairs, respectively. To
examine whether single observation pairs had a major
influence on the estimates of the parameters in the model,
we calculated the standardized delta-beta values. This
revealed considerable effects of omitting some of the
observation pairs on the coefficient for depression, but there
were no similarities in covariate patterns between these pairs,
justifying the inclusion of an interaction term in the model.
Discussion
In this matched case-control study we assessed the
importance of a variety of factors associated with age-related
cognitive impairment. The strengths of our study lie in its
matched design, the relatively large number of observation
pairs, and the availability of a broad range of information
on each of the participating subjects. Another advantage
relates to the Danish population, which is assumed to be
genetically homogenous, making it amenable for genetic
association studies. Several important findings were made
in this study. First, we confirmed findings from earlier
studies that depression (Yaffe et al 1999; Wilson et al 2004),
amounts of exercise (Laurin et al 2001), metabolic syndrome
(Stewart and Liolitsa 1999; Yaffe et al 2004),  and regular
consumption of alcohol (Pinder and Sandler 2004) modulate
the risk for cognitive impairment in elderly women. Second,
the COMT Val/Met polymorphism was identified as a genetic
risk factor potentially involved in age-related cognitive
impairment. Third, risk factors were ranked according to
their relative contribution to cognitive impairment.
Among the risk factors for age-related cognitive
impairment identified in the present study, depression
emerged as the most important. Since depression may be
more strongly associated with performance on some tasks
than with others (Comijs et al 2001), we might even have
underestimated the importance of depression as a risk factor
for cognitive impairment. Although there is evidence that
depression predisposes for cognitive impairment, the causal
relationship between these two may be much more complex
(Yaffe et al 1999; Wilson et al 2004), perhaps involving
common determinants. Cerebrovascular dysfunction could
be such a common determinant since it has been associated
with a subset of geriatric depression termed “vascular
depression” (Alexopoulos et al 1997), besides being
involved in dementia and cognitive decline.
A surrogate marker of metabolic syndrome, ie, the
combined presence of obesity and hypertriglycedemia, was
strongly associated with cognitive impairment but neither
of these two variables produced strong associations with
cognitive impairment when analyzed separately. Our
observations suggest that physical exercise, which may help
to prevent metabolic syndrome and cardiovascular disease,
also has protective effects on age-related cognitive
impairment. Due to the increasing prevalence of obesity and
metabolic syndrome in many countries, these findings may
have important implications, as they suggest that the risk
for dementia can be reduced significantly by appropriate
lifestyle adjustments.
Our study is in line with a large number of previous
studies, which found that moderate drinking protects against
cognitive decline in elderly and that consumption of
excessive amounts of alcohol has adverse effects (Pinder
and Sandler 2004). Several mechanisms may be involved
in the protective effect of alcohol on cognitive functions,
including a decreased risk for carotid atherosclerosis
(Mukamal et al 2003). Furthermore, the various antioxidant
Table 2 Multivariate conditional logistic regression analysis of
risk factors for cognitive impairment in elderly women
Variable
a OR (95% CI) p value
b
Exercise 0.002
None Referent
1, 2, or > 2 times per week 0.50 (0.32–0.78)
Consumption of alcohol 0.007
< 7 glasses per week Referent
≥ 7 glasses per week 0.49 (0.29–0.83)
Metabolic syndrome 0.01
No Referent
Yes 2.83 (1.26–6.39)
Depression 0.01
No Referent
Yes 3.24 (1.28–8.22)
APOE epsilon4-carrier 0.02
No Referent
Yes 1.76 (1.09–2.83)
COMT Val/Met polymorphism 0.08
Val/Val Referent
Val/Met 0.76 (0.45–1.29)
Met/Met 1.36 (0.74–2.53)
a The independent variables in the model are adjusted for each other. Model fit
summary: deviance = 235.33, likelihood ratio test = 41.93, df = 7, p < 0.001.
b Adjusted p values for likelihood ratio statistics.
Abbreviations: APOE, apolipoprotein E; CI, confidence interval; COMT, catechol-
O-methyltransferase; OR, odds ratio.Neuropsychiatric Disease and Treatment 2006:2(2) 232
Berg Rasmussen et al
compounds, which are often present in high amounts in some
types of beverage such as red wine, appear to have protective
effects on brain cells and cognitive functions (Dore 2005).
The 2-fold reduction in the risk for cognitive impairment
detected in the present study is in accordance with previous
findings on wine drinkers from the same geographical area
(Truelsen et al 2002).
Smoking increased the risk for cognitive impairment in
the present study although significance was not reached.
There are probably several reasons for this absence of
significance, including lack of statistical power. Moreover,
several potentially important determinants were not taken
into consideration in the present study, such as number of
years of smoking and lifetime consumption of cigarettes.
Basically our observations support previous epidemiological
findings of a detrimental effect of smoking on cognition
(Ott et al 2004; Atkinson et al 2005; Whalley et al 2005;
and studies cited by Sabbagh et al 2002). Collectively these
findings suggest that the increased risk for cerebrovascular
damage conferred by smoking (Howard et al 1998; Eguchi
et al 2004) more than outweighs its potentially beneficial
effects on age-related cognitive impairment.
The present study confirmed previous findings that
APOE genotype status affects the risk for cognitive
impairment in elderly women (Hyman et al 1996), but our
results are not in line with earlier findings of an interaction
between APOE epsilon4 genotype status and alcohol
consumption (Dufouil et al 2000; Mukamal et al 2003).
Another finding was that cognitive performance in elderly
women was associated with a variation in the COMT gene.
Apparently, the heterozygous COMT Val/Met genotype
conferred the best performance while the Met/Met genotype
was inferior. Whether this reflects an adverse effect of high
amounts of dopamine on cognitive functions is uncertain.
However, support for this view comes from observations
that the COMT Met allele enhances cognitive stability, while
it decreases cognitive flexibility by delaying the degradation
of the dopamine released upon axonal activation (Nolan et
al 2004). However, other catecholamines involved in
cognitive functions are degraded by COMT including
estrogens (Creveling 2003; Sherwin 2003). Thus, the
association between the COMT genotypes and cognitive
impairment does not necessarily implicate the dopamine
system.
The establishment of a multivariate model allowed us to
determine the relative importance of various risk factors for
age-related cognitive impairment. We found that depression
and metabolic syndrome both increased this risk
approximately 3-fold. Exercise and alcohol intake decreased
it about 2-fold, and even moderate amounts of regular
physical activity such as 1- or 2-weekly exercises decreased
the risk for cognitive impairment significantly. Relatively
small changes in the risk for cognitive impairment could be
attributed to variations in the APOE and the COMT genes.
Overall, the present study highlights the significance of
lifestyle factors and comorbid disorders with regard to age-
related cognitive impairment.
In summary, we have identified risk factors for
cognitive impairment in elderly women. Among these,
regular consumption of alcohol, physical exercise,
depression, and metabolic syndrome appeared to have a
larger impact than selected genetic risk factors. This
indicates that cognitive decline can be delayed
significantly by healthy lifestyle choices combined with
early treatment of cardiovascular metabolic syndrome and
depression, even in individuals genetically predisposed
for dementia.
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